Allurion and GLP-1: Optimizing Muscle During Weight Loss Therapy
Allurion Technologies plans to launch a clinical study combining its weight-loss program with GLP-1 agonists to address muscle loss,...
Jon Napitupulu
Binx Health and Mass General Hospital Study Shows Positive Impact on Antibiotic Stewardship
A Massachusetts General Hospital (MGH) study assessed the real-world impact of binx health’s point-of-care (POC) testing for chlamydia and...
Neuvivo’s NP001 Extends ALS Survival
Neuvivo announced promising results from a new analysis of its investigational immunotherapy NP001 for Amyotrophic Lateral Sclerosis (ALS). The...
Medidata & Tigermed Renew Partnership to Accelerate Global Trials
Medidata, a Dassault Systèmes company, and Tigermed, a global clinical research provider, extended their 13-year partnership. This renewed collaboration...
Astria Therapeutics Initiates STAR-0310 Atopic Dermatitis Trial
Astria Therapeutics has launched a Phase 1a clinical trial for STAR-0310, a monoclonal antibody designed to treat atopic dermatitis...
Pluri Secures $6.5M Investment, Acquires Cacao Company
Pluri Inc. secured a $6.5 million private investment from Alejandro Weinstein, who will join the company’s board. Simultaneously, Pluri...
Tiziana Life Sciences’ Nasal Spray Shows Promise in Spinal Cord Injury Treatment
Tiziana Life Sciences announced positive preclinical results for their intranasal anti-CD3 monoclonal antibody, foralumab, in treating traumatic spinal cord...
MiNK Therapeutics Allo-INKTs + BOT/BAL for Advanced Gastroesophageal Cancers
MiNK Therapeutics announced a presentation at the ASCO GI Symposium detailing a Phase 2 trial of its iNKT cell...
Outlook Therapeutics ON5-5010 Wet AMD Trial Results: Efficacy & Safety Unveiled
Outlook Therapeutics presented 12-week data from its NORSE EIGHT clinical trial of ONS-5010 (bevacizumab-vikg) for wet age-related macular degeneration...
Ampligen Clinical Trial Results Published for Post-COVID Conditions
AIM ImmunoTech Inc. announced final clinical study results (AMP-518) for Ampligen in treating post-COVID conditions, specifically fatigue. The study,...